標(biāo)題: Titlebook: Managing Gastrointestinal Complications of Diabetes; Joseph Sellin Book 2017 Springer International Publishing AG 2017 Diabetes.Type 2 dia [打印本頁] 作者: 出租 時(shí)間: 2025-3-21 16:13
書目名稱Managing Gastrointestinal Complications of Diabetes影響因子(影響力)
書目名稱Managing Gastrointestinal Complications of Diabetes影響因子(影響力)學(xué)科排名
書目名稱Managing Gastrointestinal Complications of Diabetes網(wǎng)絡(luò)公開度
書目名稱Managing Gastrointestinal Complications of Diabetes網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Managing Gastrointestinal Complications of Diabetes被引頻次
書目名稱Managing Gastrointestinal Complications of Diabetes被引頻次學(xué)科排名
書目名稱Managing Gastrointestinal Complications of Diabetes年度引用
書目名稱Managing Gastrointestinal Complications of Diabetes年度引用學(xué)科排名
書目名稱Managing Gastrointestinal Complications of Diabetes讀者反饋
書目名稱Managing Gastrointestinal Complications of Diabetes讀者反饋學(xué)科排名
作者: Foolproof 時(shí)間: 2025-3-21 23:04 作者: defile 時(shí)間: 2025-3-22 00:35
o 75% of patients visiting diabetes clinics report significant gastrointestinal symptoms. Includes guidelines for complication prevention, treatment, and long-term disease management..978-3-319-48661-1978-3-319-48662-8作者: Ethics 時(shí)間: 2025-3-22 05:16
Book 2017cise format provides evidence-based content with a targeted emphasis on diagnosis,?as up to 75% of patients visiting diabetes clinics report significant gastrointestinal symptoms. Includes guidelines for complication prevention, treatment, and long-term disease management..作者: 匍匐前進(jìn) 時(shí)間: 2025-3-22 10:34
Small Intestine and Colon Complications in Patients with Diabetes,entral role in their pathogenesis. Limited familiarity with these conditions associated with DM leads to delay in their recognition and appropriate management. In this chapter, the effects of DM on the small and large intestine, as well as the associated gastrointestinal problems, are discussed.作者: ATRIA 時(shí)間: 2025-3-22 13:55
Nonalcoholic Fatty Liver Disease, the absence of secondary causes of hepatic steatosis. NAFLD is a spectrum of disease that ranges from steatosis (hepatic fat without significant hepatocellular injury) to nonalcoholic steatohepatitis (NASH; hepatic fat with hepatocellular injury) to advanced fibrosis and cirrhosis.作者: 補(bǔ)充 時(shí)間: 2025-3-22 19:13
Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma,hepatitis (NASH). Patients with NAFLD, especially NASH, are at risk for developing cirrhosis and its associated complications, including hepatocellular carcinoma (HCC). With the increasing prevalence of NAFLD closely linked to the growing epidemics of diabetes mellitus and obesity, NAFLD-related HCC is expected to rise.作者: Headstrong 時(shí)間: 2025-3-23 00:55 作者: Onerous 時(shí)間: 2025-3-23 05:00 作者: 流行 時(shí)間: 2025-3-23 06:58 作者: 多山 時(shí)間: 2025-3-23 09:45 作者: arousal 時(shí)間: 2025-3-23 15:45
Small Intestine and Colon Complications in Patients with Diabetes,ea, small intestine bacterial overgrowth, constipation, and fecal incontinence is more common in diabetes mellitus (DM). Diabetic neuropathy plays a central role in their pathogenesis. Limited familiarity with these conditions associated with DM leads to delay in their recognition and appropriate ma作者: 描述 時(shí)間: 2025-3-23 21:02
Nonalcoholic Fatty Liver Disease,cause for end-stage liver disease in the United States [1]. NAFLD is characterized by an accumulation of fat (steatosis) within >5 % of hepatocytes in the absence of secondary causes of hepatic steatosis. NAFLD is a spectrum of disease that ranges from steatosis (hepatic fat without significant hepa作者: Chivalrous 時(shí)間: 2025-3-23 23:28
Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma,ntries (see Chap. .) [1]. NAFLD encompasses a broad clinicopathologic spectrum of disease ranging from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH). Patients with NAFLD, especially NASH, are at risk for developing cirrhosis and its associated complications, including hepatocellula作者: 縮減了 時(shí)間: 2025-3-24 04:37 作者: Grievance 時(shí)間: 2025-3-24 07:41
Diabetes, Cirrhosis, and Liver Transplantation,y recognized. In addition, a significant amount of experience with diabetes in the setting of liver transplantation has accumulated. In this chapter, we will examine the relationship between diabetes and cirrhosis and provide an overview of diabetes in the liver transplantation setting.作者: HARD 時(shí)間: 2025-3-24 12:17 作者: APO 時(shí)間: 2025-3-24 16:30 作者: 秘方藥 時(shí)間: 2025-3-24 19:17
Diabetes, Specific Hepatobiliary Diseases, and Treatment,esting that HCV is directly involved in the pathogenesis of diabetes. The relationship between HCV and diabetes has been studied closely, and there are three distinct processes that have been described [1]. First, insulin resistance and diabetes may simply be a result of progressive fibrosis caused 作者: Visual-Field 時(shí)間: 2025-3-25 02:10 作者: Dawdle 時(shí)間: 2025-3-25 05:50 作者: Debility 時(shí)間: 2025-3-25 11:11 作者: 類人猿 時(shí)間: 2025-3-25 13:21
Esophageal Disease in Diabetes Mellitus,ases the risk of esophageal candidiasis, and increases the risk of Barrett’s esophagus and esophageal carcinoma. Finally, “black esophagus,” or acute esophageal necrosis, is also associated with DM. These four entities and their relationship with DM will be reviewed in this section.作者: cinder 時(shí)間: 2025-3-25 16:40 作者: fastness 時(shí)間: 2025-3-25 20:40
Book 2017cise format provides evidence-based content with a targeted emphasis on diagnosis,?as up to 75% of patients visiting diabetes clinics report significant gastrointestinal symptoms. Includes guidelines for complication prevention, treatment, and long-term disease management..作者: Mumble 時(shí)間: 2025-3-26 04:07
Joseph SellinAn evidence-based overview of common gastrointestinal complications associated with Type 1 and Type 2 diabetes.Written by renowned experts in the field of gastroenterology.Includes in-depth discussion作者: Negligible 時(shí)間: 2025-3-26 04:56 作者: GROG 時(shí)間: 2025-3-26 10:07 作者: Deadpan 時(shí)間: 2025-3-26 13:04
6樓作者: 標(biāo)準(zhǔn) 時(shí)間: 2025-3-26 19:58
7樓作者: 猛然一拉 時(shí)間: 2025-3-27 00:36
7樓作者: 有助于 時(shí)間: 2025-3-27 01:49
7樓作者: 膽小鬼 時(shí)間: 2025-3-27 07:41
7樓作者: legacy 時(shí)間: 2025-3-27 13:17
8樓作者: Incorruptible 時(shí)間: 2025-3-27 15:43
8樓作者: 香料 時(shí)間: 2025-3-27 20:50
8樓作者: llibretto 時(shí)間: 2025-3-28 01:58
8樓作者: In-Situ 時(shí)間: 2025-3-28 04:10
9樓作者: debunk 時(shí)間: 2025-3-28 10:15
9樓作者: Conclave 時(shí)間: 2025-3-28 14:17
9樓作者: 系列 時(shí)間: 2025-3-28 16:21
9樓作者: 在前面 時(shí)間: 2025-3-28 20:31
10樓作者: 緩和 時(shí)間: 2025-3-29 01:03
10樓作者: Inkling 時(shí)間: 2025-3-29 03:24
10樓作者: peritonitis 時(shí)間: 2025-3-29 11:15
10樓
